<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00918515</url>
  </required_header>
  <id_info>
    <org_study_id>D0510C00001</org_study_id>
    <secondary_id>2007-003474-26</secondary_id>
    <nct_id>NCT00918515</nct_id>
  </id_info>
  <brief_title>Study to Assess the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of AZD3043</brief_title>
  <official_title>A Phase I, Single-Centre, Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous AZD3043 After Single Ascending Doses in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I, single centre, open label study to assess the safety, tolerability,
      pharmacokinetics (PK) and pharmacodynamics of intravenous AZD3043 after single ascending
      doses in healthy male volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of Vital signs data, heart rate, electrocardiogram (ECG)</measure>
    <time_frame>The measure will be taken between -20 to 150 min relative to start of administration of AZD3043.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Respiratory signs data (SpO2, EtCO2, PaO2, blood gases, respiratory frequency, volume and pattern, occurrence of apnoea;</measure>
    <time_frame>The measure will be taken between -20 to 150 min relative to start of administration of AZD3043.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK parameters for AZD3043: Cmax (Css), AUClast, AUC, lz, t½lz, CL, Vc, Vss, Vz, tlast and mean residence time in arterial and venous plasma.</measure>
    <time_frame>Arterial: Predose, 2, 5, 15, 29, 31, 32, 35, 37, 40, 45, 60, 75, 90, 150 min postdose. Venous: Predose, 2, 5, 15, 29, 31, 32, 35, 37, 40, 45, 60, 75, 90, 150, 270 min, 8h, 24h postdose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters for the metabolite (THRX 108893): Cmax (Css), AUClast, AUC, tmax, tlast, lz and t½lz in venous plasma</measure>
    <time_frame>29 min, 45 min and 150 min post dose</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>AZD3043</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD3043</intervention_name>
    <description>intravenous solution given once as intravenous infusion over 30 minutes</description>
    <arm_group_label>AZD3043</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subjects aged 18 to 45 years with suitable veins for cannulation or
             repeated venepuncture

          -  Pre-dose assessment judged without remarks by the investigator

          -  Have a Body Mass Index (BMI) between 19 and 30 kg/m2 and weight at least 50kg and no
             more than 100kg

        Exclusion Criteria:

          -  After adequate time (at least 15 minutes) of rest in supine position, abnormal vital
             signs defined as any of the following:·

          -  Systolic blood pressure (BP) &gt;140 mm Hg.·

          -  Diastolic BP &gt;90 mm Hg.

          -  Heart rate &lt;=55 or &gt;85 beats per minute

          -  Subjects with compromised airway or respiratory function as evidenced by the presence
             of Class 3 or 4 Airway, Sleep Apnoea, Neck circumference &gt; 16.5 inches (42 cm),
             Asthma, Active or recent (2 weeks) respiratory infection, or known chronic respiratory
             infection, or known chronic respirator

          -  Lack of a normal phenotype for butyrylcholinesterase (pseudo-cholinesterase)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johan Wemer</last_name>
    <role>Study Chair</role>
    <affiliation>AstraZeneca R&amp;D Södertälje</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sigridur Kalman</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Clinical Science Intervention and technology, CLINTECThe department of Anaesthosiology and Intensive care, Karolinska University hospital, Huddinge,141 86 Stockholm, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2009</study_first_submitted>
  <study_first_submitted_qc>June 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2009</study_first_posted>
  <last_update_submitted>August 27, 2009</last_update_submitted>
  <last_update_submitted_qc>August 27, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 28, 2009</last_update_posted>
  <responsible_party>
    <name_title>Stephen Kanes, Medical Science Director</name_title>
    <organization>AstraZeneca Pharmaceuticals US</organization>
  </responsible_party>
  <keyword>Sedation</keyword>
  <keyword>Anaesthesia</keyword>
  <keyword>Safety</keyword>
  <keyword>tolerability</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>pharmacodynamics</keyword>
  <keyword>healthy male volunteers</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

